title: Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.
abstract: Microbial infections are hypothesized to play a key role in the mechanism leading to type 1 diabetes (T1D). We used the LEW1.WR1 rat model of Kilham rat virus (KRV)-induced islet destruction to better understand how virus infection triggers T1D. Inoculation of the LEW1.WR1 rat with KRV results in systemic inflammation followed by insulitis and islet destruction 2-4 weeks post-infection. In this study, we evaluated the effect of treatment with the anti-inflammatory histone deacetylase inhibitor (HDACi) ITF-2357 on KRV-induced immunity and disease progression. Administering LEW1.WR1 rats with KRV plus ITF-2357 on 14 consecutive days beginning on the day of infection protected animals from islet infiltration and T1D. ITF-2357 reversed KRV-induced T and B cell accumulation in the spleen or pancreatic lymph nodes on day 5 following infection. Moreover, ITF-2357 reduced the expression level of KRV-induced p40 subunit of IL-12/IL-23 in spleen cells in vitro and in the peripheral blood in vivo. ITF-2357 suppressed the KRV-induced expression of transcripts for IRF-7 in the rat INS-1 beta cell line. ITF-2357 increased the virus-induced IL-6 gene expression in the spleen, but did not alter the ability of LEW1.WR1 rats to develop normal KRV-specific humoral and cellular immune responses and clear the virus from the pancreatic lymph nodes, spleen, and serum. Finally, ITF-2357 reversed virus-induced modulation of bacterial communities in the intestine early following infection. The data suggest that targeting innate immune pathways with inhibitors of HDAC might represent an efficient therapeutic strategy for preventing T1D.
  
  
  CONCLUSIONS
  Microbial infections have been implicated in triggering type 1 diabetes in humans and animal models. The LEW1.WR1 rat develops inflammation and T1D following infection with Kilham rat virus. The histone deacetylase inhibitor ITF-2357 suppresses virus-induced inflammation and prevents diabetes. ITF-2357 prevents T1D without altering virus-specific adaptive immunity or virus clearance. ITF-2357 therapy may be an efficient approach to prevent T1D in genetically susceptible individuals.
authors: Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO, 80045, USA.
authors: Naoko
authors: N
authors: Hara
authors: Aimon K
authors: AK
authors: Alkanani
authors: Charles A
authors: CA
authors: Dinarello
authors: Danny
authors: D
authors: Zipris
mesh_terms: D056704:Adaptive Immunity / Q000187:drug effects; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000096:biosynthesis; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000821:virology*; D004195:Disease Models, Animal; D005260:Female; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000276:immunology / Q000382:microbiology / Q000821:virology; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000378:metabolism*; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000494:pharmacology; D007113:Immunity, Innate / Q000187:drug effects; D007249:Inflammation / Q000276:immunology / Q000378:metabolism* / Q000821:virology*; D008221:Lymphoid Tissue / Q000187:drug effects / Q000276:immunology / Q000473:pathology / Q000821:virology; D008297:Male; D064307:Microbiota; D017992:Parvovirus / Q000276:immunology; D051381:Rats; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology
chemical_list: D016207:Cytokines; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D006655:Histone Deacetylases; C502418:givinostat hydrochloride
references: J Virol. 2002 Oct;76(19):10044-9
references: 12208983
references: Adv Exp Med Biol. 2010;654:585-610
references: 20217515
references: Mol Med. 2011 May-Jun;17(5-6):353-62
references: 21365126
references: Mol Ther. 2003 Nov;8(5):707-17
references: 14599803
references: Diabetes Metab Res Rev. 2011 Nov;27(8):824-9
references: 22069267
references: Clin Diagn Lab Immunol. 1997 Nov;4(6):764-8
references: 9384304
references: Nat Rev Drug Discov. 2009 Dec;8(12):969-81
references: 19855427
references: J Immunol. 2012 Oct 15;189(8):3805-14
references: 22988033
references: J Immunol. 2001 Nov 1;167(9):5395-403
references: 11673558
references: Clin Immunol. 2009 Apr;131(1):11-23
references: 19185542
references: Immunol Rev. 2005 Apr;204:232-49
references: 15790362
references: Nature. 2005 Apr 7;434(7034):772-7
references: 15800576
references: J Immunol. 2006 Apr 15;176(8):5015-22
references: 16585598
references: Immunol Cell Biol. 2011 Jul;89(5):640-9
references: 21321581
references: J Immunol. 2003 Apr 1;170(7):3592-602
references: 12646622
references: Ernst Schering Res Found Workshop. 2006;(56):45-60
references: 16331856
references: Diabetologia. 2007 Apr;50(4):779-89
references: 17265033
references: Mol Med. 2011 May-Jun;17(5-6):397-403
references: 21308151
references: Mol Med. 2011 May-Jun;17(5-6):369-77
references: 21193899
references: Mol Med. 2011 May-Jun;17(5-6):442-7
references: 21373721
references: Mol Med. 2011 May-Jun;17(5-6):378-90
references: 21274504
references: J Neuroimmunol. 2005 Jul;164(1-2):10-21
references: 15885809
references: Clin Immunol. 2013 Feb;146(2):112-9
references: 23314185
references: Clin Immunol. 2009 Jul;132(1):103-15
references: 19328037
references: Contrib Microbiol. 2000;4:163-77
references: 10941577
references: J Immunol. 2005 Jan 1;174(1):131-42
references: 15611235
references: Curr Mol Med. 2009 Feb;9(1):52-68
references: 19199942
references: Science. 1991 Nov 15;254(5034):1010-3
references: 1658938
references: Mol Med. 2011 May-Jun;17(5-6):333-52
references: 21556484
references: Arthritis Rheum. 2011 May;63(5):1452-8
references: 21538322
references: J Immunol. 2011 Apr 1;186(7):3986-96
references: 21368229
references: Nat Rev Drug Discov. 2002 Apr;1(4):287-99
references: 12120280
references: J Immunol. 2007 Jan 15;178(2):693-701
references: 17202329
references: Clin Immunol. 2010 Jun;135(3):401-11
references: 20167539